TY - JOUR
T1 - Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
AU - Bollani, Lina
AU - Baraldi, Eugenio
AU - Chirico, Gaetano
AU - Dotta, Andrea
AU - Lanari, Marcello
AU - Del Vecchio, Antonello
AU - Manzoni, Paolo
AU - Boldrini, Antonio
AU - Paolillo, Piermichele
AU - Di Fabio, Sandra
AU - Orfeo, Luigi
AU - Stronati, Mauro
AU - Romagnoli, Costantino
PY - 2015
Y1 - 2015
N2 - Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease.Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
AB - Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease.Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
KW - RSV
KW - RSV
UR - http://hdl.handle.net/10807/71566
U2 - 10.1186/s13052-015-0203-x
DO - 10.1186/s13052-015-0203-x
M3 - Article
SN - 1720-8424
VL - 41
SP - 97
EP - 97
JO - THE ITALIAN JOURNAL OF PEDIATRICS
JF - THE ITALIAN JOURNAL OF PEDIATRICS
ER -